News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.
The company plans to use proceeds from the round to further commercialize products based on its mass spec multinozzle emitter array (MEA) technology.
The company sells miniaturized mass spectrometers and microfluidic separations systems for use in applied markets and life science and drug research.
Called direct infusion–shotgun proteome analysis, the approach uses ion mobility in place of liquid chromatography to enable higher-throughput experiments.
The firm also discussed recent studies comparing its UltraSeek lung cancer assay with more established liquid biopsy tests to detect drug-resistant mutations.
The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.
